HARVARD MEDICAL SCHOOL
CURRICULUM VITAE

Date Prepared: **07/18/2018**
Name: **Mary Elizabeth Aronow, MD**

Education:

1997	BS (*honors, distinction*)	Human Ecology	Cornell University
2000	Postbaccalaureate	Premedical	Bryn Mawr College
2006	MD (*cum laude*)	Medicine	Yale University School of Medicine

Postdoctoral Training:

07/06-06/07	Internship	Internal Medicine	Brigham and Women's Hospital (BWH)
07/07-06/10	Residency	Ophthalmology	Cleveland Clinic
09/10-08/11	Fellowship #1	Ophthalmic Oncology	Cleveland Clinic
07/13-06/14	Fellowship #2	Medical Retina	National Eye Institute/NIH (NEI/NIH)

Faculty Academic Appointments:

11/11-12/12	Clinical Associate	Ophthalmology	Cleveland Clinic
08/14-07/17	Assistant Professor	Ophthalmology	Johns Hopkins
09/17-	Assistant Professor	Ophthalmology	Massachusetts Eye and Ear (MEE)

Appointments at Hospitals/Affiliated Institutions:

12/16-07/17	Assistant Professor	Oncology-Joint Appt.	Johns Hopkins
09/17-	Assistant Professor	Ophthalmology	MEE
09/17-	Clinical Associate	Ophthalmology	Massachusetts General Hospital

Other Professional Positions:

08/00-08/02	Research Assistant; Thomas Thornhill Lab	BWH
11/16-	Professional Advisory Board	Tuberous Sclerosis Alliance

Major Administrative Leadership Positions:

Local

2015-2017	Assistant Director, Retina Fellowship Program	Johns Hopkins

Committee Service:

Local

2016-2017	Retina Clinical Subcommittee Member	Johns Hopkins

Institutional

2008-2009	House Staff Association, Ophthalmology	Cleveland Clinic
2015	Retina Faculty Search Committee	Johns Hopkins
2015-2017	Retina Fellowship Selection Committee	Johns Hopkins

National

2015	Panelist (10 members, 4 USA ocular oncologists) Ocular Toxicity Symposium *FDA initiative to develop standard criteria for grading ocular toxicity from cancer drugs*	Food and Drug Administration (FDA)

International

2018	Tuberous Sclerosis Alliance Chair, Clinical Consensus Group (Ophthalmology)	MEE
2018	World Ophthalmology Congress Abstract Review Committee	MEE
2018	International Society of Ocular Oncology International Review Committee	MEE

Professional Societies:

2007-	American Academy of Ophthalmology (AAO), Member 01/17-12/17 AAO Retina/Vitreous Knowledge Base Panel
2007-	Association for Research in Vision and Ophthalmology (ARVO), Member
2011-	International Society of Ocular Oncology (ISOO), Member
2016-	Women in Ophthalmology (WIO), Member
2016-	Women in Ocular Oncology (WOO), Member

Editorial Activities:

Ad hoc Reviewer

Ophthalmology
The Journal of the American Medical Association (JAMA) Ophthalmology
American Journal of Ophthalmology
British Journal of Ophthalmology
Investigative Ophthalmology and Visual Science
Ocular Oncology and Pathology
Orbit
Ophthalmic Genetics
Ophthalmology Retina
Retina: The Journal of Retinal and Vitreous Diseases
Clinical and Experimental Ophthalmology
Ocular Immunology and Inflammation
Digital Journal of Ophthalmology
BMC Ophthalmology

BMC Cancer
Current Eye Research
Faculty of 1000 (Ophthalmic Oncology Section)

Other Editorial Roles

2016	Section Editor (Ophthalmic Oncology)	*Advances in Ophthalmology & Optometry*
2016	Section Editor (Uveal Tumors)	*Manual of Retinal Diseases*
2017-	Editorial Board Member	*Ophthalmic Genetics*
2017-	Associate Editor	*BMC Cancer*

Honors and Prizes:

1993	Senator Robert C. Byrd National Merit Scholarship
1995	Kappa Omicron Nu National Honor Society, Cornell University Chapter
1996	Honors Research Program, Cornell University
1996	Outstanding Junior Award, Cornell University
1997	Outstanding Senior Award, Cornell University
2002	Summer Research Grant Recipient, Yale School of Medicine
2003	Intensive Pedagogical Research Program, Yale School of Medicine
2006	Alpha Omega Alpha Honor Medical Society, Yale School of Medicine Chapter
2011	Best Ophthalmology Fellow Paper, Cleveland Clinic
2016	Pooled Professor Fund Grant Recipient (Top-scoring grant proposal), Johns Hopkins

Report of Funded and Unfunded Projects

Past
(Johns Hopkins Hospital and University School of Medicine)

2015-2017 Co-investigator	A phase II, multi-center, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration
2015-2017 Co-investigator	A phase III, multi-center, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age related macular degeneration
2015-2017 Co-investigator	A phase II multi-center, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of luminate (ALG-1001) as compared to avastin in the treatment of diabetic macular edema
2017 Co-investigator	An open-label, phase Ib/II study investigating recommended phase II dose, safety, tolerability and preliminary efficacy of TAK-659 in adult patients with relapsed or refractory acute myelogenous leukemia
2017 Co-investigator	A multi-center, randomized, open-label, 3-arm phase III study of encorafenib + cetuximab plus or minus binimetinib vs. irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI)/cetuximab with a safety lead-in of encorafenib + binimetinib + cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer

2017 Co-investigator	MATCH treatment subprotocol H: phase II study of dabrafenib and trametinib in patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
2017 Co-investigator	A phase I study of ASP2215 in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
2017 Co-investigator	A phase I study evaluating safety, tolerability, pharmacokinetics of escalating doses of AGS62P1 given as monotherapy in subjects with acute myeloid leukemia
2016-2017 PI	The role of circulating plasma tumor DNA in monitoring response to therapy in uveal melanoma Pooled Professors Fund, Wilmer Eye Institute, Johns Hopkins Award: $50,000 This project seeks to correlate levels of circulating plasma tumor DNA with response to plaque brachytherapy and with development of metastatic disease in patients with uveal melanoma. (Target patient enrollment was met for year 1 and preliminary data were generated. This collaborative work is now being directed by a colleague, Zelia Correa, MD, PhD who is leading the ophthalmic oncology service at Johns Hopkins.)

Current

2017- Sub-investigator	Light activated AU-011 to treat primary choroidal melanoma NCT03052127 Industry sponsored This phase 1B/2 open-label, ascending single and repeat dose clinical trial investigates the use of a first-in-class therapy (a light-activated virus-like nanoparticle conjugate) for the treatment of small choroidal melanoma.

Report of Local Teaching and Training

Teaching of Students in Courses:

2015	Ophthalmology Clinical Skills Module Medical students	Johns Hopkins 4-hr session

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

2015	Uveal Melanoma Update Radiation oncology fellows	Johns Hopkins 1-hr lecture
2016	Retinoblastoma Update Pediatric oncology fellows	Johns Hopkins 1-hr lecture
2015-2016	Echography Workshop Ophthalmology residents and fellows	Johns Hopkins 4-hr session
2017	Retinoblastoma Ophthalmology residents	Johns Hopkins 1-hr lecture

Clinical Supervisory and Training Responsibilities:

2014-2017	Supervision of retina fellows in the operating room	300 hrs/year, Johns Hopkins
2014-2017	Supervision of retina fellows and ophthalmology residents in clinic	400 hrs/year, Johns Hopkins
2015-2016	Preceptor, international visiting scholars, Wilmer ophthalmic oncology service	150 hrs/year, Johns Hopkins
2017-	Supervision of retina fellows in the operating room	150 hrs/year, MEE
2017-	Supervision of retina fellows and ophthalmology residents in clinic	300 hrs/year, MEE

Mentored Trainees and Faculty:

2015-2017 Tahreem Mir, MD/ Research Fellow, Wilmer Retina Division, Johns Hopkins
Career stage: research fellow. Mentoring role: clinical and research advisor. Accomplishments: multiple first-authored scholarship of mentored research.

2015-2017 Alice Zhang, MD. Assistant Professor, University of North Carolina, Department of Ophthalmology (Former Clinical Fellow, Wilmer Retina Division, Johns Hopkins). Career stage: clinical fellow. Mentoring role: research advisor. Accomplishments: multiple first- authored scholarship of mentored research and meeting presentations.

Formal Teaching of Peers (e.g., CME and other continuing education courses):
No presentations below were sponsored by outside entities

2013-2016	What's New in Diabetic Retinopathy Johns Hopkins CME	Annual course Baltimore, MD
2013-2016	Current Concepts in Ophthalmology Johns Hopkins CME	Annual course Baltimore, MD
2014	Intraocular Tumors: An Overview Wilmer Eye Institute CME	Single course Bel Air, MD
2015	Advances in Uveal Melanoma Wilmer Eye Institute CME	Single course Bel Air, MD
2015-2017	Melanoma Update Johns Hopkins CME	Annual course Arundel Mills, MD
2016	Topics in Medicine: Intraocular Tumors Johns Hopkins CME	Single course Baltimore, MD

Local Invited Presentations:
No presentations below were sponsored by outside entities

2011 FISH-based prognostication for uveal melanoma/Speaker series
Cleveland Ophthalmological Society, Cleveland, OH

2017 Retinoblastoma update/Speaker series
Johns Hopkins 34th Annual Wilmer Nursing Conference, Baltimore, MD

2018 Ocular complications of immunotherapy
MGH Severe Immunotherapy Complications (SIC) Service Rounds

2018 Topics in tuberous sclerosis complex: ophthalmology
MGH Annual Tuberous Sclerosis Complex Symposium

Report of Regional, National and International Invited Teaching and Presentations

No presentations below were sponsored by outside entities

Regional

2010	Intraocular tumors Sugarbush Eye and Laser Center Educational Seminar Ashland, OH
2015	Recognizing ocular tumors Evidenced Based Care in Optometry Conference Ellicott City, MD
2017	Grand rounds invited lecturer: The spectrum of intraocular lymphoma Department of Ophthalmology, University of Maryland Baltimore, MD

National

2009-2012	Intraocular tumors Joint Commission on Allied Health Personnel in Ophthalmology San Francisco-2009, Chicago-2010, Orlando-2011, Cleveland-2012
2010	Paraneoplastic vitelliform retinopathy Wills Oncology Fellows Association Annual Meeting Chicago, IL
2011	Uveal melanoma: trends in incidence, treatment, and survival (selected oral abstract) The American Academy of Ophthalmology Orlando, FL
2015-2017	Selected cases in ocular oncology Wills Intraocular Tumor Symposium Philadelphia, PA
2015	Ocular assessment methods and technology Food and Drug Administration (FDA) Ocular Toxicity Symposium Silver Spring, MD
2015	Effect of aspirin use on progression of age-related macular degeneration in the age-related eye disease study 2 (AREDS2) participants (selected oral abstract) Association for Research in Vision and Ophthalmology Orlando, FL
2015	Ocular manifestations of HIF2-α mutations (selected oral abstract) American Association of Ophthalmic Oncologists and Pathologists Las Vegas, NV
2016	Top 5 advances in the past decade: uveal melanoma American Academy of Ophthalmology, Ocular Oncology and Pathology Subspecialty Day Chicago, IL
2016	Moderator: Ocular tumors and pathology American Academy of Ophthalmology Chicago, IL
2016	Moderator: Poster tours, retina section American Academy of Ophthalmology Chicago, IL
2016	Intraocular tumors American Society of Ophthalmic Registered Nurses Chicago, IL

2016 Primary vitreoretinal lymphoma
Intraocular Lymphoma Conference
Baltimore, MD

2016 Using technology in daily practice
Women in Ophthalmology Annual Meeting
Williamsburg, VA

2017 Bilateral choroidal osteoma in childhood
Atlantic Coast Retina Conference
Baltimore, MD

2017 Moderator: Tumor time
Macula Meeting
Baltimore, MD

2017 Basic ocular oncology instruction course: Assessment of an amelanotic choroidal mass
The American Academy of Ophthalmology
New Orleans, LA

2017 Moderator
The American Association of Ophthalmic Oncologists and Pathologists Annual Meeting
New Orleans, LA

2018 Grand rounds invited lecturer: The spectrum of ocular lymphoma
University of South Florida
Tampa, FL

2018 Grand rounds invited lecturer: Update on uveal melanoma
University of South Florida
Tampa, FL

2018 Relationship of BAP1 tumor predisposition syndrome and uveal melanoma
Macula Meeting
Philadelphia, PA

2018 One of these things is not like the other
Atlantic Coast Retina Conference
Philadelphia, PA

2018 Moderator: Tumors and uveitis
Macula Meeting
Philadelphia, PA

International

2011 FISH-based prognostication for uveal melanoma (selected oral abstract)
International Society of Ocular Oncology
Buenos Aires, Argentina

2011 FISH: making heads or tails of techniques (selected oral abstract)
International Society of Ocular Oncology
Buenos Aires, Argentina

2011 Paraneoplastic vitelliform retinopathy (selected oral abstract)
International Society of Ocular Oncology
Buenos Aires, Argentina

2013 Ocular adnexal lymphoma: assessment of a TNM staging system (selected oral abstract)
International Society of Ocular Oncology
Cleveland, OH

2013 Advances in prognostication for uveal melanoma
OMICS International Eye Disorders & Treatment Conference
Baltimore, MD

2015	MALT lymphoma Pan American Association of Ophthalmology Bogotá, Columbia
2015	Moderator: Oncology subspecialty day: clinico-pathological correlation Pan American Association of Ophthalmology Bogotá, Columbia
2015	Uveal melanoma: prognostication and treatment Pan American Association of Ophthalmology Bogota, Columbia
2016	Prognostication for uveal melanoma World Ophthalmology Congress Guadalajara, Mexico
2016	Uveal melanoma: new frontiers World Ophthalmology Congress Guadalajara, Mexico
2017	Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013) (selected oral abstract) International Society of Ocular Oncology Sydney, Australia
2017	Bilateral choroidal osteoma (selected oral abstract) International Society of Ocular Oncology Sydney, Australia
2017	Primary vitreoretinal lymphoma Pan American Association of Ophthalmology Lima, Peru
2017	Widefield retinal angiography and imaging Pan American Association of Ophthalmology Lima, Peru
2017	Moderator: Basic ocular oncology course Pan American Association of Ophthalmology Lima, Peru
2017	Retinoblastoma research One Retinoblastoma World Meeting Washington DC,USA

Report of Clinical Activities and Innovations

Current Licensure and Certification:

2010-2013	Ohio Medical License
2013-	Maryland Medical License
2013-	Certification, American Board of Ophthalmology
2017-	Massachusetts Medical License

Practice Activities:

2011-2012	Ambulatory Care	Ophthalmology Cleveland Clinic	4 half-day sessions/week
2014-2017	Ambulatory Care	Ocular Oncology/Medical Retina Johns Hopkins	5 half-day sessions/week
2014-2017	Surgery	Ocular Oncology Johns Hopkins	3 half-day sessions/week
2017-	Ambulatory Care	Ocular Oncology/Medical Retina	4-5 half-day sessions/week

2017-	Surgery	MEE Ocular Oncology MEE	1 day session/week

Clinical Innovations:

Clinical program for intravitreal delivery of chemotherapy for retinoblastoma at Johns Hopkins 2015-2017	Intravitreal chemotherapy, initially developed in abroad, is useful for treating residual vitreous seeding following primary treatment of retinoblastoma. I implemented the first intravitreal chemotherapy program for retinoblastoma at Johns Hopkins. This involved partnering with our chemotherapy pharmacy, pharmaceutical suppliers, medical instrument suppliers, and operating room teams to deliver safe and efficacious care to pediatric patients with retinoblastoma.
Clinical program for patients with tuberous sclerosis complex (TSC) at MGH 2017-	Individuals and their families travel from across the United States and internationally to receive comprehensive care at the Herscot Center for Tuberous Sclerosis Complex. The ophthalmic features of TSC are important diagnostic criteria for establishing clinical diagnosis. I am working with Dr. Elizabeth Thiele, Director of the TSC program at MGH, to build a program where ocular examination is coordinated with MRI/CT scan. Examination under anesthesia provides an opportunity for thorough assessment of ocular manifestations (astrocytic hamartoma and achromic patch). It also allows findings to be documented to further our understanding of the natural history and response to therapy of fundus lesions, particularly as a subset of astrocytic hamartoma demonstrate aggressive features that threaten vision. Providing efficient scheduling of ocular examinations at the time of systemic imaging (where anesthesia is generally required in the setting of TSC) avoids the need for additional separate exposures to general anesthesia and saves time and hospital resources. I helped to successfully implement similar programs at the Cleveland Clinic and at Johns Hopkins and look forward to continuing to develop this element of the TSC Service at MEE/MGH.

Report of Education of Patients and Service to the Community

No presentations below were sponsored by outside entities

Activities

2014	Macular News Interview with journalist David Seftel regarding the use of aspirin and its effects on age-related macular degeneration (https://macularnews.org/2014/05/06/arvo-2014-dr-beth-aronow/)
2014	Medscape Medical News Interview with journalist Marcia Frellick on 3-D printer derived facial prostheses for patients with eye cancer (http://www.medscape.com/viewarticle/834475)
2014-	Expert Opinion/Medical-Legal Consultation (Various Law Firms) Rawls, McNelis & Mitchell, Norfolk, VA (2014) Williamson Law LC, Richmond, VA (2016) Cline, Williams, Wright, Johnson & Oldfather, LLP, Lincoln, NE (2016) The Klein Law Firm, Houston, TX (2016) Hofeld and Schaffner, Chicago, IL (2016)

2015 USA Today
Interview with journalist Liz Szabo on “phantom eye syndrome” that patients may experience following enucleation
(https://www.usatoday.com/story/news/2015/05/21/phantom-eye-syndrome/27669949/)
2016 Columbia Wellness Center
Seminar for local public entitled: Seeing into the future: vision and the aging eye

Educational Material for Patients and the Lay Community:
No educational materials below were sponsored by outside entities.

Books, monographs, articles and presentations in other media (e.g., video and websites, movies, television and radio) that educate the public about medicine, health or biomedical sciences

2015 Diagnosis and treatment of eye tumors: Q&A, Johns Hopkins Clinical Connection (educational patient video)
(https://clinicalconnection.hopkinsmedicine.org/videos/diagnosis-and-treatment-of-eye-tumors)

Educational material or curricula developed for non-professional students

2015 NIH-Focus on Fellows Career Development Curriculum
Participated in a full-day retreat for medical and college students with emphasis on careers in academia.

Patient educational material

2012 Eye Plaque Brachytherapy (patient guide), Cleveland Clinic Taussig Cancer Institute
2013 Intraocular Melanoma Tests and Procedures (patient handout), NIH
2014 Plaque brachytherapy (informational guide), Johns Hopkins

Report of Scholarship

***Some entries appear by maiden name: Mary Elizabeth Turell**

Peer-Reviewed Scholarship in print or other media:

Research Investigations

1. **Turell ME**, Wang A, Bellare A. Quantification of the effect of cross-path motion on the wear rate of ultra-high molecular weight polyethylene. *Wear.* 2003;255:1034-39.

2. **Turell ME**, Bellare A. A study of the nanostructure and tensile properties of ultra-high molecular weight polyethylene. *Biomaterials.* 2004 Aug;25(17):3389-98. PMID: 15020111.

3. **Turell ME**, Friedlaender G, Wang A, Thornhill TS, Bellare A. The effect of counterface roughness on the wear of UHMWPE for rectangular wear paths. *Wear.* 2005;259:984-91.

4. Bistolfi A, **Turell ME**, Lee Y, Bellare A. Tensile and tribological properties of high-crystallinity radiation crosslinked UHMWPE. *J Biomed Mater Res Part B: Appl Biomater*. 2009 Jul;90(1):137-44. doi: 10.1002/jbm.b.31265. PMID: 18985795.

5. **Turell ME**, Morrison SC, Traboulsi EI. Spondylometaphyseal dysplasia with cone-rod dystrophy. *Ophthalmic Genet*. 2010 Mar;31(1):12-7. doi: 10.3109/13816810903397812. PMID: 20141353.

6. Singh AD, **Turell ME**, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. *Ophthalmology.* 2011 Sep;118(9):1881-5. doi: 10.1016/j.ophtha.2011.01.040. PMID: 21704381.

7. Singh A, **Aronow ME**, Sun Y, Bebek G, Sauntharajah Y, Schoenfield L, Biscotti B, Tubbs R, Triozzi P, Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. *Invest Ophthalmol Vis Sci.* 2012 Jun 5;53(7):3331-9. doi: 10.1167/iovs.11-9027. PMID: 22511634.

8. **Aronow ME**, Adamus G, Mones A, Wang Y, Chan C, Singh A. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature. *Surv Ophthalmol.* 2012 Nov;57(6):558-64. doi: 10.1016/j.survophthal.2012.02.004. PMID: 22784677.

9. **Aronow ME**, Nakagawa J, Gupta A, Traboulsi E, Singh A. Tuberous sclerosis complex: genotype/phenotype correlation of retinal findings. *Ophthalmology.* 2012 Sep;119(9):1917-23. doi: 10.1016/j.ophtha.2012.03.020. PMID: 22608477.

10. Wang Y, Abu-Asab MS, Li W, **Aronow ME**, Singh AD, Chan CC. Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy. *BMC Ophthalmol.* 2012 Nov 13;12:56. doi: 10.1186/1471-2415-12-56. PMID: 23148706.

11. **Aronow ME**, Sun Y, Sauntharajah Y, Biscotti C, Tubbs R, Triozzi P, Singh A. Monosomy 3 by FISH in uveal melanoma: variability in techniques and results. *Surv Ophthalmol*. 2012 Sep;57(5):463-73. doi: 10.1016/j.survophthal.2011.12.004. PMID: 22658782.

12. **Aronow ME**, Portell CA, Rybicki LA, Sweetenham JW, Singh AD. Ocular Adnexal Lymphoma: Assessment of a Tumor-Node-Metastasis Staging System. *Ophthalmology.* 2013 Sep;120(9):1915-9. doi: 10.1016/j.ophtha.2013.02.003. PMID: 23664470.

13. **Aronow ME**, Portell CA, Sweetenham JW, Singh AD. Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. *Ophthalmology.* 2014 Jan;121(1):334-41. doi: 10.1016/j.ophtha.2013.09.004. PMID: 24144449.

14. Portell CA, **Aronow ME**, Rybicki LA, Macklis R, Singh AD, Sweetenham JW. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype. *Clin Lymphoma Myeloma Leuk*. 2014 Jun;14(3):203-10. doi: 10.1016/j.clml.2013.10.011. PMID: 24417911.

15. Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, **Aronow ME**, Triozzi PL, Singh A, Cook JR, Sauntharajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA. Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication. *Cancer Genet*. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. PMID: 25442074.

16. Pacak K, Chew EY, Pappo AS, Yang C, Lorenzo FR, Wilson MW, **Aronow ME**, Young JA, Popovic V, Zhuang Z. Ocular manifestations of hypoxia-inducible factor-2α paraganglioma-somatostatinoma-polycythemia syndrome. *Ophthalmology.* 2014 Nov;121(11):2291-3. doi: 10.1016/j.ophtha.2014.06.019. PMID: 25109928.

17. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, **Aronow ME**, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J.Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. *Am J Ophthalmol*. 2016 Aug;168:13-23. doi:10.1016/j.ajo.2016.04.017. PMID: 27130369.

18. Singh AD, Medina CA, Singh N, **Aronow ME**, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. *Br J Ophthalmol*. 2016 Apr;100(4):456-62. doi: 10.1136/bjophthalmol-2015-306921. PMID: 26231747.

19. Engelhard S, Shah C, **Aronow ME**, Reddy A. Malpractice litigation in ocular oncology. *Ocul Oncol Pathol*. 2018;4:135-40. doi:10.1159/000479559. PMID: 29765942.

20. **Aronow ME**, Topham AK, Singh AD. Uveal melanoma: 5 year update on incidence, treatment, and survival (SEER 1973-2013). *Ocul Oncol Pathol*. 2018 Apr;4(3):145-51. doi: 10.1159/000480640. PMID: 29765944.

21. Shah S, Correa ZM, Schefler A, **Aronow ME**, et al. Trends in radiation practices for female ocular oncologists in North America: a collaborative study of the international society of ocular oncology. *Ocul Oncol Pathol* (accepted April 2018, in press).

Other peer-reviewed scholarship

1. **Turell ME**, Char D. Eyelid melanoma with negative sentinel lymph node biopsy and perineural spread. *Arch Ophthalmol.* 2007Jul;125(7):983-4. PMID: 17620588.

2. **Turell ME**, Hayden BC, McMahon JT, Schoenfield LR, Singh, AD. Uveal schwannoma surgery. *Ophthalmology.* 2009 Jan;116(1):163-163.e6. doi: 10.1016/j.ophtha.2008.08.045. PMID: 19118703.

3. **Turell ME**, Singh AD. Vascular tumors of the retina and choroid: diagnosis and treatment. *Middle East Afr J Ophthalmol.* 2010 Jul;17(3):191-200. doi: 10.4103/0974-9233.65486. PMID: 20844673.

4. **Turell ME**, Leonardy NJ, Singh AD. A unique presentation of grouped congenital hypertrophy of the retinal pigment epithelium. *Ophthalmic Genet.* 2011 Sep;32(3):162-4. doi: 10.3109/13816810.2011.562956. PMID: 21425957.

5. Sachdeva R, **Turell ME**, Meadows SR, Emch TM, Singh AD. Congenital intradiploic arachnoid cyst presenting as painless proptosis. *J AAPOS.* 2011 Dec;15(6):601-3. doi: 10.1016/j.jaapos.2011.07.013. PMID: 22153410.

6. Mirchia K, **Turell ME**, Singh AD. Imaging modalities for uveal melanoma. *Eur Ophthalmic Rev.* 2012;6:56-63.

7. **Turell ME**, Tubbs RR, Biscotti CV, Singh AD. Uveal melanoma: prognostication. *Monogr Clin Cytol*. 2012;21:55-60. doi: 10.1159/000331035. available. PMID: 22024584.

8. **Aronow ME**, Singh AD. The use of imaging in the diagnosis and management of intraocular lymphoma. *Int Ophthalmol Clin.* 2012 Fall;52(4):199-208. doi: 10.1097/IIO.0b013e318265d4e3. PMID: 22954942.

9. Singh AD, Pabon S, **Aronow ME**. Management of radiation maculopathy. *Ophthalmic Res.* 2012;48 Suppl 1:26-31. doi: 10.1159/000339844. PMID: 22907147.

10. Chen S, **Aronow ME**, Wang C, Shen D, Chan CC. Classical pathology of sympathetic ophthalmia presented in a unique case. *Open Ophthalmol J*. 2014 Jun 27;8:32-8. doi: 10.2174/1874364101408010032. PMID: 25067979.

11. **Aronow ME**, Chew EY. Age-related eye disease study 2: perspectives, recommendations, and unanswered questions. *Curr Opin Ophthalmol*. 2014 May;25(3):186-90. doi: 10.1097/ICU.0000000000000046. PMID: 24614146.

12. **Aronow ME**. Ocular adnexal lymphoma: evidence-based treatment approach. *Int Ophthalmol Clin*. 2015 Winter;55(1):97-109. doi: 10.1097/IIO.0000000000000049. PMID: 25436496.

13. **Aronow ME**, Shen D, Hochman J, Chan CC. Intraocular lymphoma models. *Ocul Oncol Pathol*. 2015 Apr;1(3):214-22. doi: 10.1159/000370158. PMID: 27171354.

14. **Aronow ME**. Intra-arterial chemotherapy for retinoblastoma: experience matters, but risks remain (Invited Commentary). *Ophthalmology* 2018;125(11):1812. doi: 10.1016/j.ophtha.2018.08.020. PMID: 30318041.

Non-peer reviewed scholarship in print or other media:

Proceedings of meetings or other non-peer reviewed scholarship

1. Bellare A, Fitz W, Gomoll A, **Turell ME**, Scott R, Thornhill T. Using nanotechnology to improve the performance of acrylic bone cements. *Orthopaedic Journal at Harvard Medical School*. 2002;4:93-6.

2. Morris K, **Turell ME**, Ahmed S, Ghazi A, Vora S, Lane M, Entigar LD. The 2003 anatomy ceremony: a service of gratitude. *Yale J Biol Med.* 2002 Sep-Dec;75(5-6):323-9. PMID: 14580114.

Reviews, chapters, monographs and editorials

1. **Turell ME**, Saunthararajah Y, Triozzi PL, Tubbs RR, Crabb JW, Singh AD. Recent advances in prognostication for uveal melanoma. *Ophthalmology International.* 2010: 45-8.

2. **Turell ME**, Tubbs RR, Biscotti CV, Singh AD. Uveal melanoma: prognostication. Monogr Clin Cytol 2011;21:55-60. doi: 10.1159/000331035. PMID: 22024584.

3. **Turell ME**, Tubbs RR, Biscotti CV, Singh AD. Uveal melanoma prognostication. In: Biscotti CV, Singh AD, eds. FNA of Ophthalmic Tumors. Basel: Karger; 2011: 55-60.

4. **Turell ME**, Singh AD. Nonvascular hamartomas. In: Wright KW, Spiegel PH, eds. Pediatric Ophthalmology and Strabismus, Vol. 1, 3rd ed. New York, NY: Springer-Verlag; 2012: 928-37.

5. **Turell ME**, Hayden BC, Schoenfield LR, Singh AD. Intraocular tumors. In: Hayden BC, Schoenfield LR, Singh AD eds. Ophthalmic Ultrasonography. London, UK: Elsevier Inc.; 2012: 111-31.

6. **Turell ME**, Singh AD. Diagnosis and treatment of intraocular lymphoma. *Review of Ophthalmology.* 2012: 40-7.

7. **Aronow ME**, Biscotti CV, Chan CC, Singh AD. The role of biopsy in the assessment of uveal melanoma. *Retinal Physician.* 2012;9:13-17.

8. **Aronow ME**, Schachat AP, Peereboom DM, Singh AD. Primary vitreoretinal lymphoma. In: Ryan SJ, ed. Retina. 5th ed. London: Saunders-Elsevier 2013; Vol 3: 2373-8.

9. **Aronow ME**, Singh AD, Peereboom DM. Vitreoretinal lymphoma: staging and treatment. In: Singh

AD, ed. Essentials in Ophthalmology: Ocular and Adnexal Lymphoma. New York, NY: Springer; 2013: 85-92.

10. **Aronow ME**, Sweetenham JW, Singh AD. Staging and treatment: adnexal lymphoma. In: Singh AD, ed. Essentials in Ophthalmology: Ocular and Adnexal Lymphoma. New York, NY: Springer; 2013: 77-84.

11. **Aronow ME**, Singh AD. Clinical features and diagnostic evaluation: ocular and adnexal lymphoma. In: Singh AD, ed. Essentials in Ophthalmology. New York, NY: Springer; 2013: 57-69.

12. **Aronow ME**, Singh AD, Bergstrom C. Uveal vascular tumors. In: Grossniklaus HE, ed. Pocket Guide to Ocular Oncology and Pathology. New York, NY: Springer-Verlag; 2013:323-31.

13. **Aronow ME**, Singh AD. Radiation therapy: conjunctival and eyelid tumors. In: Singh AD, Pelayes DE, Seregard S, Maklis R. eds. Ophthalmic Radiation Therapy. Basel, Switzerland: Karger; 2013:85-93.

14. **Aronow ME**, Singh AD. Radiation therapy: conjunctival and eyelid tumors. *Dev Ophthalmol*. 2013; 52:85-93. doi: 10.1159/000351062. PMID: 23989129.

15. Mezaros L, **Aronow ME.** What ophthalmologists need to know about ocular cancer. *Ophthalmology Times*. 2014;Apr. http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/content/tags/intraocular-lymphomas/what-ophthalmologists-need-know-about-ocular-c?page=full

16. Medina CA, **Aronow ME**, Singh AD. Cataract associated with intraocular tumors. In: Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. 2nd Edition. New York, NY: Springer; 2014: 141-50.

17. Courtney RJ, Singh RP, **Aronow ME**, Singh AD. Ocular paraneoplastic diseases. In: Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. 2nd Edition. New York, NY: Springer; 2014: 133.

18. Ahluwalia MS, Dahiya S, **Aronow ME**, Peereboom DM, Singh AD. Primary central nervous system and retinal lymphoma. In: Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. 2nd Edition. New York, NY: Springer; 2014: 75-90.

19. **Aronow ME**, Hill BT, Singh AD. Orbital and adnexal lymphoma. In: Singh AD, Damato BE, eds. Clinical Ophthalmic Oncology. 2nd Edition. New York, NY: Springer; 2014: 123-40.

20. **Aronow ME**, Murray TG, Shields CL. Key Opinion Leaders: Diagnosing and managing choroidal nevi and melanoma. *Retina Times*. 2015;33(5):32-41.

21. Channa R, **Aronow ME**. Uveal lymphoma. In: Medina CA, Townsend JH, Singh AD, eds. Manual of Retinal Disease: A Guide to Diagnosis and Management. New Delhi, India: Springer; 2016: 209-12.

22. Mir T, **Aronow ME**. Assessment of amelanotic choroidal mass. In: Medina CA, Townsend JH, Singh AD, eds. Manual of Retinal Disease: A Guide to Diagnosis and Management. New Delhi, India: Springer; 2016: 185-90.

23. Van Landingham S, **Aronow ME**. Choroidal hemangioma. In: Medina CA, Townsend JH, Singh AD, eds. Manual of Retinal Disease: A Guide to Diagnosis and Management. New Delhi, India: Springer; 2016: 191-6.

24. Channa R, Yohannan J, **Aronow ME**. Intravitreal chemotherapy for retinoblastoma. In: Yanoff ed.

Advances in Ophthalmology and Optometry. Philadelphia, USA: Elsevier; 2016: 273-85.

25. Zhang A, Salek S, **Aronow ME**. Update on TNM staging for uveal melanoma. In: Yanoff ed. Advances in Ophthalmology and Optometry. Philadelphia, USA: Elsevier; 2016: 261-72.

26. **Aronow ME**, Chan CC. Uveal lymphoma. In: Gupta V, Nguyen Q, LeHoang P, Herbort C eds. The Uveitis Atlas. New Delhi, India: Springer; 2016 (in press; available May 2019).

27. **Aronow ME**, Yeung I, Chan CC. Vitreoretinal lymphoma. In: Gupta V, Nguyen Q, LeHoang P, Herbort C eds. The Uveitis Atlas. New Delhi, India: Springer; 2016 (in press; available May 2019).

28. **Aronow ME**, Schachat AP, Peereboom DM, Singh AD. Primary vitreoretinal lymphoma. In: Ryan SJ, ed. Retina. 6th ed. London, UK: Elsevier; 2017: 2675-81.

29. **Aronow ME**. Intraocular lymphoma. In: Arevalo F, Chablani J. eds. Retinal and Choroidal Imaging in Systemic Diseases. Singapore: Springer Nature; 2018: 231-48.

30. **Aronow ME**, Singh AD. Hamartomas of the retina: astrocytic and retina/RPE. In: Ehlers JP ed. The Retina Illustrated. New York, NY: Thieme; 2018 (in press-submitted October 2017).

31. Medina CA, **Aronow ME**, Amescua G, Singh AD. Tumor associated cataract. In: Singh AD and Damato BE eds. Clinical Ophthalmic Oncology (3rd edition). New York, NY: Springer; 2018 (in press-submitted May 2018).

32. Lorek, BH, **Aronow ME**, Singh AD. Diagnostic techniques: ophthalmic ultrasonography. In: Singh AD and Damato BE eds. Clinical Ophthalmic Oncology (3rd edition). New York, NY: Springer; 2018 (in press-submitted May 2018).

33. **Aronow ME**, Hill BT, Singh AD. Orbital and adnexal lymphoma. In: Singh AD and Damato BE eds. Clinical Ophthalmic Oncology (3rd edition). New York, NY: Springer; 2018 (in press- submitted May 2018).

34. **Aronow ME**, Ahluwalia MS, Peereboom DM, Singh AD. Primary central nervous system and retinal lymphoma. In: Singh AD and Damato BE eds. Clinical Ophthalmic Oncology (3rd edition). New York, NY: Springer; 2018 (in press-submitted May 2018).

35. **Aronow ME**. Imaging advances for choroidal melanoma. Review of Ophthalmology. September 25, 2018: https://www.reviewofophthalmology.com/article/imaging-advances-for-choroidal-melanoma

Case reports

1. **Turell ME**, Schoenfield LR, Singh AD. The blind painful eye. *Advanced Ocular Care.* 2010;1:29-30.

2. Medina CA, **Aronow ME**, Singh AD. Amelanotic choroidal mass. *Advanced Ocular Care.* 2012;3:33-5.

3. **Aronow ME**, Crowell EI, Reddy AK. Bilateral choroidal osteoma of childhood. JAMA Ophthalmol (accepted October 2018, in press).

Book and film reviews

1. Shields JA, Shields CL. Eyelid, Conjunctival, and Orbital Tumors & Intraocular Tumors: An

Atlas and Textbook. Vol 1-2. 2nd ed. Philadelphia: 2008 Lippincott, Williams, & Wilkins, Philadelphia, 2008. Review in: *Br J Ophthalmol*. 2010;94:958.

2. Hugh Williams. The Olympian Ophthalmologist. Copyright: The Royal College of Ophthalmologists (DVD Video) Review in: *Br J Ophthalmol*. 2011;95:752-753.

Professional educational materials or reports, in print or other media:

1. **Turell ME**, Bellare A. A USAXS study of the effects of crystallization conditions on the morphology of UHMWPE. Advanced Photon Source User Activity Report, Argonne National Laboratory 2001.

2. **Turell ME**, Bellare A. A USAXS study of dispersion of barium sulfate particles in poly (methyl methacrylate) bone cement. Advanced Photon Source User Activity Report, Argonne National Laboratory 2002.

3. **Turell ME**, Bellare A. A USAXS study of the morphology of high pressure crystallized ultra-high molecular weight polyethylene. Advanced Photon Source User Activity Report, Argonne National Laboratory 2002.

4. **Turell ME**, Bellare A. A USAXS study of the effects of crystallization conditions on the morphology of UHMWPE. Advanced Photon Source User Activity Report, Argonne National Laboratory 2002.

5. **Aronow ME.** Diagnostic dilemmas in retina and neuro-ophthalmology. Jan 2017. American Academy of Ophthalmology Webinar. https://store.aao.org/webinar-grand-rounds-diagnostic-dilemmas-in-retina-and-neuro-ophthalmology.html

6. Correa ZM, Demirci H, **Aronow ME**. Ocular surface squamous neoplasia: trends in topical chemotherapy. American Academy of Ophthalmology Clinical Update. August 2018 (https://www.aao.org/eyenet/article/ossn-trends-in-topical-chemotherapy?august-2018)

Clinical Guidelines and Reports:

1. **Turell ME**, Singh AD. Uveal malignant melanoma. http://www.firstconsult.com (Aug 2011).

2. **Turell ME**, Singh AD. Retinoblastoma. http://www.firstconsult.com (Aug 2011).

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings:

1. **Aronow ME**, Klein ML, Clemons TE, Ferris FL, Agron E, Blodi BA, Chew EY, The AREDS2 Rearch Group. Effect of aspirin use on progression of age-related macular degeneration in the age-related eye disease study 2 (AREDS2) participants. *Invest Ophthalmol Vis Sci.* (Abstract). 2014 Apr; 55(13):2993.

2. **Aronow ME**, Goldstein, D, Chan CC. Bilateral epibulbar masses: atypical presentation of a rare disease. The 2015 Meeting of the International Society of Ocular Oncology. Paris, France. June 2015 (juried poster: P41).

3. **Aronow ME,** Wenick A. Moderator: Poster tours: Retina, vitreous. The 2016 Annual Association for Research in Vision and Ophthalmology Meeting. Chicago, IL (PT10).

4. Zhang AY, **Aronow ME**. Choroidal osteoma in the pediatric population. The 2017 Annual Association for Research in Vision and Ophthalmology Meeting. Baltimore, MD (juried poster:

1786-AO426).

5. **Aronow ME,** Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER: 1973-2013). The 2017 Annual Association for Research in Vision and Ophthalmology Meeting. Baltimore, MD (juried poster: 4411-AO270).

6. **Aronow ME,** Rajaii F, Rodriguez FJ. Giant cell tumor of soft tissue. The 2017 American Association of Ophthalmic Oncologists and Pathologists Annual Meeting. New Orleans, LA (juried poster: #9).

7. **Aronow ME**, Wang J, Lane AM, Oxenreiter M, Gragoudas ES, Kim IK. Macular perfusion status in eyes with choroidal melanoma treated with prophylactic ranibizumab after proton beam irradiation. The 2018 Annual Association for Research in Vision and Ophthalmology Meeting. Honolulu, HI (juried poster: 4301 - C0275).

8. Shah S, Correa ZM, Schefler AC, Kogachi K, **Aronow ME**, et al. Trends in radiation practices for female ocular oncologists in North America. The 2018 Annual Association for Research in Vision and Ophthalmology Meeting. Honolulu, HI (juried poster: 3623 - A0284).

9. **Aronow ME**, Daniels AB. Moderator: Poster session: Ocular complications of therapy: trends, imaging, treatment. The 2018 Annual Association for Research in Vision and Ophthalmology Meeting. Honolulu, HI (C0271 - C0287).

Narrative Report

Overview:

I am an ophthalmologist with dual fellowship training in ophthalmic oncology and medical retina. My clinical and surgical practice (~80% effort) encompasses the full spectrum of pediatric and adult eye cancer care. My research (~10% effort) focuses on furthering our understanding of eye cancer with the ultimate goal of improving treatments and outcomes for patients. As an educator (~10% effort) my efforts are directed towards training ophthalmology residents, fellows, medical students, and visitors from institutions nationally and internationally.

Clinical Expertise and Innovation:

I was recruited to the Johns Hopkins to be the first dedicated comprehensive ophthalmic oncologist at the Wilmer Eye Institute and tasked with building a full-service eye cancer program. Prior to joining the faculty, I was a full-time faculty member at the Cleveland Clinic Cole Eye Institute. My practice scope has involved some of the most complex diseases in ophthalmology: uveal melanoma, retinoblastoma, intraocular lymphoma, ocular surface neoplasia, orbital tumors, benign tumors (hamartomas and others), phakomatoses (particularly tuberous sclerosis complex and von Hippel Lindau disease), paraneoplastic conditions, and ocular toxicities from cancer therapy (particularly immunotherapy). This involves multidisciplinary coordination of services, including radiation oncology, chemotherapy pharmacies, and pediatric/adult medical and surgical oncology. I work closely with the teams at academic cancer centers, such as the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (where I held a joint appointment), and presently with the Dana Farber and the Massachusetts General Hospital (MGH). My major practice contributions have included launching the first intravitreal chemotherapy program for children with retinoblastoma at Johns Hopkins. As a member of the national professional advisory board for the Tuberous Sclerosis Alliance and chair (ophthalmology section) for the Clinical Consensus Group, I have worked closely with tuberous sclerosis centers of excellence such as the Kennedy Krieger Institute in Baltimore, MD and the Herscot Center for Tuberous Sclerosis Complex (TSC) at MGH. As part of both the major and minor diagnostic criteria, the ophthalmic features of TSC are central to establishing diagnosis. I am working with Dr. Elizabeth Thiele, Director of the TSC program at MGH, to build a patient program for ocular screening. Examinations are frequently performed under sedation at the same time as MRI/CT scan. Examination under anesthesia provides an opportunity for thorough assessment of ocular manifestations (astrocytic hamartoma and achromic patch) and allows findings to be documented in order to further our understanding of the natural history and response to therapy of fundus lesions, particularly as a subset of astrocytic hamartoma demonstrate aggressive features that threaten vision.

Investigation:

I am interested in pushing the field of molecular biomarker analytics forward as a new frontier for uveal melanoma. With Hopkins grant support, I investigated the role of plasma tumor DNA (ptDNA) in monitoring response to therapy. Our group was among the first to use droplet digital PCR for detection of ptDNA in this population. Ultimately, the goal is to develop targeted therapies for uveal melanoma, and I believe that ptDNA may serve as a sensitive marker of effective new treatments. Through these efforts and other scholarly pursuits, I have had the privilege of delivering more than 25 invited talks nationally and more than 15 invited presentations internationally since 2009. I have served as an editor for multiple textbooks and am on the editorial board of *Ophthalmic Genetics* and *BMC Cancer*.

Teaching and Education:

As the assistant retina fellowship director at Johns Hopkins, I supervised trainees during their 2-year fellowship program. In addition, I devote over 400 hours of clinical and surgical teaching time per year to medical students, residents, and fellows. At Johns Hopkins, I hosted 4 international visiting scholars on the ophthalmic oncology service. I look forward to hosting visiting scholars at Harvard Medical School. I have also regularly presented lectures for faculty and trainees from our collaborating teams such as radiation oncology and pediatric oncology.

Summary:

I am an ocular oncologist with expertise in the full spectrum of pediatric and adult eye cancer. My focus is to make an impact on patient care and survival outcomes through the development of novel markers of disease response and newer therapies for ocular tumors.